Navigating Telehealth Prescribing of Hormone Therapy: State-Specific Controlled Substance Requirements

The expansion of telehealth services has revolutionized healthcare delivery, offering convenience and accessibility for various conditions, including hormone replacement therapy (HRT) and testosterone replacement therapy (TRT). However, the prescribing of controlled substances, such as testosterone (a Schedule III controlled substance), via telehealth is subject to a complex and evolving patchwork of federal and state regulations. Healthcare businesses, including telehealth platforms, medspas, and primary care practices, must navigate these rules carefully to ensure compliance and avoid significant legal and regulatory repercussions.

Federal Framework and the Ryan Haight Act

At the federal level, the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires an in-person medical evaluation before a controlled substance can be prescribed via the internet. This act was designed to combat rogue online pharmacies and ensure patient safety. However, the law includes several exceptions, one of which allowed for temporary waivers during a declared Public Health Emergency (PHE).

During the COVID-19 PHE, the Drug Enforcement Administration (DEA) issued waivers that permitted practitioners to prescribe controlled substances via telehealth without an initial in-person examination, provided certain conditions were met, including the use of an audio-visual, real-time, two-way interactive communication system. These waivers significantly facilitated access to telehealth services, including for HRT/TRT involving controlled substances.

Source: DEA Practitioner's Manual, Chapter 3: Controlled Substance Prescribing Source Published At: March 2020 (Manual revision date)

Post-PHE Landscape and Proposed DEA Rules

The federal COVID-19 PHE officially ended on May 11, 2023. Consequently, the DEA's waivers for the in-person examination requirement for controlled substance prescribing via telehealth expired. The DEA initially proposed new rules in February 2023 that would have largely reinstated the in-person requirement for controlled substances prescribed via telehealth, with some limited exceptions. However, due to significant public comment and concerns about access to care, the DEA issued a temporary rule in May 2023, extending the full set of telemedicine flexibilities for controlled substances until November 11, 2023, and then further extended them until December 31, 2024. This extension allows the DEA to review public comments and promulgate a new permanent rule.

Source: DEA Telemedicine Prescribing of Controlled Substances Source Published At: May 2023 (Initial temporary rule), November 2023 (Extension)

This means that, for now, federal law continues to permit the prescribing of controlled substances, including testosterone, via telehealth without an initial in-person visit, provided the practitioner is acting in accordance with applicable state law.

State-Specific Regulations: The Primary Compliance Challenge

While federal law currently allows for telehealth prescribing of controlled substances under the temporary rules, state laws and medical board regulations are often more restrictive and are the primary determinant of compliance for practitioners. Each state has its own definition of what constitutes a valid patient-practitioner relationship for telehealth, especially when controlled substances are involved. These state-specific requirements can vary widely and may include:

• Initial In-Person Examination: Many states, even pre-PHE, required an initial in-person examination before a controlled substance could be prescribed via telehealth. While some states temporarily waived this during the PHE, many have since reinstated or clarified this requirement. For example, states like Texas (Texas Occupations Code § 111.005) or Florida (Florida Statutes § 456.47) have specific requirements for telehealth prescribing, particularly for controlled substances, which may include an initial in-person visit or specific exceptions.
• Synchronous Audio-Visual Requirement: Most states mandate the use of synchronous (real-time, two-way) audio-visual technology for telehealth encounters involving controlled substances to ensure a thorough assessment.
• Prescribing Limits: Some states impose limits on the duration or quantity of controlled substances that can be prescribed via telehealth without an in-person follow-up.
• Documentation Standards: Enhanced documentation requirements are common for controlled substance prescribing via telehealth, emphasizing the need for a comprehensive patient history, physical examination (even if conducted remotely), and medical necessity.
• Prescriber Location and Patient Location: Practitioners must be licensed in the state where the patient is located at the time of the telehealth visit. This is a fundamental principle of telehealth practice.
• Specific Rules for APPs: The authority of Advanced Practice Providers (APPs) like Nurse Practitioners (NPs) and Physician Assistants (PAs) to prescribe controlled substances via telehealth, and the level of physician supervision required, varies significantly by state. For instance, in states like California, NPs have broad prescribing authority, but specific rules for telehealth and controlled substances still apply (California Business and Professions Code § 2725, § 3502.1).

Examples of State Approaches (Illustrative, not exhaustive):

• Texas: The Texas Medical Board has specific rules for telemedicine, including requirements for establishing a patient-physician relationship and the conditions under which controlled substances may be prescribed. Generally, an appropriate patient-physician relationship must be established, and the standard of care must be met. (Texas Occupations Code § 111.005, Texas Administrative Code Title 22, Part 9, Chapter 174).
  • Source: Texas Medical Board Telemedicine Rules
  • Source Published At: Varies by rule update
• Florida: Florida has specific statutes regarding telehealth, including requirements for establishing a patient-practitioner relationship. While the state has embraced telehealth, prescribing controlled substances via telehealth without an initial in-person exam has historically been restricted, with some exceptions for psychiatric conditions. (Florida Statutes § 456.47).
  • Source: Florida Statutes Chapter 456.47
  • Source Published At: Varies by legislative session
• California: The Medical Board of California's guidance emphasizes that the standard of care remains the same whether care is delivered in-person or via telehealth. While California generally allows for the establishment of a patient-physician relationship via telehealth, specific considerations for controlled substances must be met, often aligning with federal requirements and professional judgment. (California Business and Professions Code § 2290.5).
  • Source: Medical Board of California Telehealth Guidelines
  • Source Published At: Varies by guideline update

These examples highlight the necessity for healthcare providers and businesses to consult the specific statutes, administrative codes, and medical board guidance for each state in which they operate or intend to operate.

Implications for Telehealth Hormone Therapy Programs

For businesses offering TRT/HRT via telehealth, the state-specific nature of controlled substance prescribing creates several critical compliance considerations:

1. Jurisdictional Awareness: Every practitioner must be licensed in the state where the patient is located, and the practice must comply with that state's specific telehealth and controlled substance prescribing laws.
2. Patient-Practitioner Relationship: Businesses must ensure their intake and assessment protocols meet each state's definition of establishing a valid patient-practitioner relationship, especially for controlled substances. This may involve specific diagnostic tests, comprehensive history taking, and synchronous audio-visual consultations.
3. Controlled Substance Monitoring: Adherence to state Prescription Drug Monitoring Program (PDMP) requirements is mandatory for controlled substances. Practices must integrate PDMP checks into their workflow to prevent diversion and ensure patient safety.
4. Documentation: Meticulous documentation of all telehealth encounters, assessments, treatment plans, and rationale for prescribing controlled substances is crucial. This includes documenting medical necessity, informed consent, and any discussions about risks and benefits.
5. Ongoing Monitoring and Adaptation: Regulatory landscapes are dynamic. Businesses must have mechanisms in place to continuously monitor changes in state and federal telehealth and controlled substance regulations and adapt their policies and procedures accordingly.

Conclusion

The telehealth prescribing of hormone therapy involving controlled substances like testosterone is a high-risk area for regulatory non-compliance. While federal temporary rules currently provide flexibility, the ultimate authority often rests with individual states. Healthcare businesses must prioritize a comprehensive, state-by-state analysis of these regulations to ensure lawful and ethical practice, safeguarding both their operations and patient well-being. Proactive compliance strategies, including legal counsel and robust internal policies, are indispensable for any entity operating in this complex space.